CLINICAL TRIALS PROFILE FOR RANEXA

All Clinical Trials for Ranexa

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00099788 ↗	Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes	Completed	The TIMI Study Group	Phase 3	2004-10-01	MERLIN-TIMI 36 is a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of ranolazine during acute and long-term treatment in approximately 5,500 patients with non-ST elevation acute coronary syndromes (ACS) treated with standard therapy. The primary efficacy endpoint in MERLIN-TIMI 36 is time to first occurrence of any element of the composite of cardiovascular death, myocardial infarction or recurrent ischemia in patients with non-ST elevation ACS receiving standard therapy. The study also evaluates the safety of long-term treatment with ranolazine compared to placebo.
NCT00099788 ↗	Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes	Completed	Gilead Sciences	Phase 3	2004-10-01	MERLIN-TIMI 36 is a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of ranolazine during acute and long-term treatment in approximately 5,500 patients with non-ST elevation acute coronary syndromes (ACS) treated with standard therapy. The primary efficacy endpoint in MERLIN-TIMI 36 is time to first occurrence of any element of the composite of cardiovascular death, myocardial infarction or recurrent ischemia in patients with non-ST elevation ACS receiving standard therapy. The study also evaluates the safety of long-term treatment with ranolazine compared to placebo.
NCT00570089 ↗	Microvascular Coronary Disease In Women: Impact Of Ranolazine	Completed	CV Therapeutics	Phase 2	2007-04-01	1. To evaluate the impact of ranolazine extended-release tablets in women with subendocardial ischemia due to microvascular endothelial dysfunction on myocardial ischemia (Cardiac Magnetic Resonance (CMR) extent, severity. 2. To evaluate the impact of ranolazine extended-release tablets in women with subendocardial ischemia due to microvascular endothelial dysfunction on the outcomes of angina (Seattle Angina Questionnaire (SAQ), WISE angina frequency, Duke Activity Status Inventory(DASI) and SF-36).
NCT00570089 ↗	Microvascular Coronary Disease In Women: Impact Of Ranolazine	Completed	Cedars-Sinai Medical Center	Phase 2	2007-04-01	1. To evaluate the impact of ranolazine extended-release tablets in women with subendocardial ischemia due to microvascular endothelial dysfunction on myocardial ischemia (Cardiac Magnetic Resonance (CMR) extent, severity. 2. To evaluate the impact of ranolazine extended-release tablets in women with subendocardial ischemia due to microvascular endothelial dysfunction on the outcomes of angina (Seattle Angina Questionnaire (SAQ), WISE angina frequency, Duke Activity Status Inventory(DASI) and SF-36).
NCT00574756 ↗	Effect of Ranolazine on Echocardiographic Indices of Diastolic Dysfunction	Terminated	University of California, San Diego	N/A	2007-12-01	The purpose of this study is to evaluate the effects of ranolazine, an FDA-approved medication for the treatment of angina, on heart function by using echocardiography.
NCT00832572 ↗	Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy	Terminated	Gilead Sciences	Phase 4	2009-01-01	This study was to determine whether ranolazine was effective in the treatment of neuropathic pain in patients with coronary artery disease. Eligibility required neurological examination by the study doctor and assessment of the patient's pain. Eligible participants were randomized to receive blinded study medication for a total of 12 weeks.
NCT00914316 ↗	Supervised Treadmill Exercise and Ranolazine for Intermittent Claudication of Lower Extremities	Terminated	William Beaumont Hospitals	N/A	2009-05-01	The goal of this study is to evaluate whether supervised treadmill exercise combined with ranolazine 1000 mg twice daily provides an incremental benefit in absolute walking distance over supervised exercise alone in patients with stable claudication. Investigators also seek to determine if the administration of ranolazine provides a sustained benefit after the completion of a supervised exercise regimen. Lastly, investigators wish to determine whether both exercise and ranolazine improves peak oxygen consumption and anaerobic threshold in patients with stable claudication.

Clinical Trial Conditions for Ranexa

Condition Name

Condition Name for Ranexa
Intervention	Trials
Coronary Artery Disease	8
Angina	6
Myocardial Ischemia	3
Type 2 Diabetes Mellitus	3

Condition MeSH

Condition MeSH for Ranexa
Intervention	Trials
Myocardial Ischemia	15
Coronary Artery Disease	15
Coronary Disease	11
Ischemia	8

Clinical Trial Locations for Ranexa

Trials by Country

Trials by Country for Ranexa
Location	Trials
United States	107
Poland	8
Canada	8
Germany	7
France	5

Trials by US State

Trials by US State for Ranexa
Location	Trials
Florida	8
Massachusetts	7
California	7
Maryland	5
Louisiana	5

Clinical Trial Progress for Ranexa

Clinical Trial Phase

Clinical Trial Phase for Ranexa
Clinical Trial Phase	Trials
Phase 4	16
Phase 3	7
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Ranexa
Clinical Trial Phase	Trials
Completed	27
Terminated	9
Unknown status	8

Clinical Trial Sponsors for Ranexa

Sponsor Name

Sponsor Name for Ranexa
Sponsor	Trials
Gilead Sciences	29
Brigham and Women's Hospital	3
University of Florida	3

Sponsor Type

Sponsor Type for Ranexa
Sponsor	Trials
Other	52
Industry	31
U.S. Fed	1